Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.45 |
| ▸ | JAK1 | P23458 | 6/20 | 0.44 |
| ▸ | JAK2 | O60674 | 5/20 | 0.44 |
| ▸ | TYK2 | P29597 | 4/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24621132 | 0.81 | AR (0.40) | NLRP3KDM4EALDH1A1CYP2C19 | |
| SCHEMBL12124191 | 0.80 | ALPI (0.49) | JAK1JAK2TYK2JAK3GSK3A | |
| SCHEMBL24506420 | 0.80 | GABRD (0.40) | NLRP3MAPTALDH1A1CYP2C19SMN1; SMN2 | |
| SCHEMBL23139017 | 0.79 | NLRP3 (0.53) | KMT2ANLRP3KDM4EPOLBALDH1A1 | |
| SCHEMBL20703132 | 0.79 | NLRP3 (0.53) | KMT2ANLRP3KDM4EPOLBALDH1A1 | |
| SCHEMBL14125781 | 0.77 | GSK3A (0.44) | KMT2AJAK1JAK2TYK2JAK3 | |
| SCHEMBL12968057 | 0.77 | GSK3A (0.44) | JAK1JAK2TYK2JAK3KDM4E | |
| SCHEMBL14149257 | 0.77 | SMN1; SMN2 (0.44) | JAK1JAK2TYK2JAK3KDM4E | |
| SCHEMBL18623452 | 0.77 | GSK3A (0.44) | JAK1JAK2TYK2JAK3KDM4E | |
| SCHEMBL14125630 | 0.77 | GSK3A (0.44) | JAK1JAK2TYK2JAK3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407409-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20180186772-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA CALIFORNIA, INC. | 2018-07-05 | — | — | US | disclosed |
| EP-3336084-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2018-06-20 | — | — | EP | disclosed |
| US-9944626-B2 | 6-(5-hydroxy-1H-pyrazol-1-YL)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-20170275271-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA CALIFORNIA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9708296-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-18 | — | — | US | disclosed |
| US-20160251337-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9345713-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-24 | — | — | US | disclosed |
| EP-2978752-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2016-02-03 | — | — | EP | disclosed |
| US-20150224113-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2015-08-13 | — | — | US | disclosed |
| US-9040522-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-26 | — | — | US | disclosed |
| US-20140296200-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2014-10-02 | — | — | US | disclosed |
| WO-2014160810-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE DERIVATIVES AND THEIR USE AS PHD INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150224113-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | SIRT1, SIRT3, SIRT5 | KMT2A 856/4885NLRP3 378/4885JAK1 2354/4885 |
| US-20180186772-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | KMT2A 440/4885NLRP3 471/4885JAK1 1536/4885 |
| US-20170275271-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | KMT2A 440/4885NLRP3 471/4885JAK1 1536/4885 |
| US-20140296200-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | KMT2A 440/4885NLRP3 471/4885JAK1 1536/4885 |
| US-10407409-B2 | 6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD | HIF1AN, EGLN3, EGLN2 | KMT2A 440/4885NLRP3 471/4885JAK1 1536/4885 |
| US-20160251337-A1 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD | HIF1AN, EGLN3, EGLN2 | KMT2A 440/4885NLRP3 471/4885JAK1 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.